Eltrombopag: ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
Study summary
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver
Exclusion Criteria:
Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.
Primary outcome measure(s)
•To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag. — 3-6 months after receiving eltombopag the incidence and severity of liver dysfunction in ITP patients
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.